Regadenoson: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
GeraldChi (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators
8,887 edits
No edit summary
GeraldChi (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators
8,887 edits
No edit summary
Line 1: Line 1:
{{Drugbox
{{DrugProjectFormSinglePage
|authorTag=
 
Gerald Chi
 
<!--Overview-->
 
|genericName=
 
Regadenoson
 
|aOrAn=
 
a
 
|drugClass=
 
 
 
|indication=
 
 
 
|hasBlackBoxWarning=
 
Yes
 
|adverseReactions=
 
 
 
<!--Black Box Warning-->
 
|blackBoxWarningTitle=
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>
 
* Content
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
 
|contraindications=
 
* Condition1
 
<!--Warnings-->
 
|warnings=
 
* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* '''Pregnancy Category'''
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
 
|administration=
 
* Oral
 
* Intravenous
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
 
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
 
|overdose=
 
===Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
 
|drugBox=
 
{{Drugbox2
| Verifiedfields = changed
| Verifiedfields = changed
| verifiedrevid = 413312613
| verifiedrevid = 413312613
Line 50: Line 446:
| synonyms = 1-[6-amino-9-[(2''R'',3''R'',4''S'',5''R'')-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- ''N''-methylpyrazole-4-carboxamide
| synonyms = 1-[6-amino-9-[(2''R'',3''R'',4''S'',5''R'')-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- ''N''-methylpyrazole-4-carboxamide
}}
}}
__NOTOC__
{{SI}}
{{CMG}}


==Overview==
<!--Mechanism of Action-->
'''Regadenoson''' ([[International Nonproprietary Name|INN]], code named '''CVT-3146''') is an [[Adenosine A2a receptor|A<sub>2A</sub>]] [[adenosine receptor]] [[agonist]] that is a coronary [[vasodilator]]. It produces maximal [[hyperemia]] quickly and maintains it for an optimal duration that is practical for radionuclide [[myocardial perfusion imaging]].<ref name="pmid15261132">{{cite journal |author=Cerqueira MD |title=The future of pharmacologic stress: selective A2A adenosine receptor agonists |journal=Am. J. Cardiol. |volume=94 |issue=2A |pages=33D–40D; discussion 40D–42D |year=2004 |month=July |pmid=15261132 |doi=10.1016/j.amjcard.2004.04.017 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002914904005934}}</ref>
 
|mechAction=
 
*
 
<!--Structure-->
 
|structure=
 
*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
 
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
 
|PK=
 
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
 
|clinicalStudies=
 
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
 
|howSupplied=
 
*
 
<!--Patient Counseling Information-->
 
|fdaPatientInfo=
 
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
 
|alcohol=
 
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
 
|brandNames=
 
* ®<ref>{{Cite web | title = | url = }}</ref>
 
<!--Look-Alike Drug Names-->
 
|lookAlike=
 
* A® — B®<ref name="www.ismp.org">{{Cite web  | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
 
<!--Drug Shortage Status-->
 
|drugShortage=
}}
 
<!--Pill Image-->
 
{{PillImage
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
|drugName=
|NDC=
|drugAuthor=
|ingredients=
|pillImprint=
|dosageValue=
|dosageUnit=
|pillColor=
|pillShape=
|pillSize=
|pillScore=
}}
 
<!--Label Display Image-->
 
{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}
 
{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}
 
<!--Category-->


It was approved by the [[United States]] [[Food and Drug Administration]] on April 10, 2008 and is marketed by [[Astellas Pharma]] under the tradename '''Lexiscan'''.<ref>[http://www.astellas.us/press_room/docs/FINAL_LEXISCANAPPROVAL041008.pdf CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM)<!-- Bot generated title -->]</ref> It has now gained approval in the [[European Union]] and is being sold under the name of Rapiscan. It is currently being marketed by [[GE Healthcare]] and is being sold in both the United Kingdom and Germany.
[[Category:Cardiovascular Drugs]]
[[Category:Drug]]


Regadenoson has a 2- to 3-minute [[biological half-life]], as compared with [[adenosine]]'s 30-second half-life. Regadenoson stress protocols using a single [[Bolus (medicine)|bolus]] have been developed, obviating the need for an intravenous line.  Regadenoson stress tests are not affected by the presence of [[beta blockers]], as regadenoson vasodilates but does not stimulate beta [[adrenergic receptor]]s.{{Citation needed|date=December 2008}}


==References==
{{Reflist|2}}


[[Category:Vasodilators]]
[[Category:Vasodilators]]
[[Category:Cardiovascular Drugs]]
[[Category:Cardiovascular Drugs]]
[[Category:Drug]]
[[Category:Drug]]

Revision as of 19:21, 26 July 2014

{{DrugProjectFormSinglePage |authorTag=

Gerald Chi


|genericName=

Regadenoson

|aOrAn=

a

|drugClass=


|indication=


|hasBlackBoxWarning=

Yes

|adverseReactions=



|blackBoxWarningTitle= Title

|blackBoxWarningBody= ConditionName:

  • Content


|fdaLIADAdult=

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage


|offLabelAdultGuideSupport=

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Regadenoson in adult patients.


|offLabelAdultNoGuideSupport=

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Regadenoson in adult patients.


|fdaLIADPed=

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Regadenoson in pediatric patients.


|offLabelPedGuideSupport=

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Regadenoson in pediatric patients.


|offLabelPedNoGuideSupport=

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Regadenoson in pediatric patients.


|contraindications=

  • Condition1


|warnings=

  • Description

Precautions

  • Description


|clinicalTrials=

There is limited information regarding Clinical Trial Experience of Regadenoson in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

|postmarketing=

There is limited information regarding Postmarketing Experience of Regadenoson in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

|drugInteractions=

  • Drug
  • Description


|useInPregnancyFDA=

  • Pregnancy Category

|useInPregnancyAUS=

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Regadenoson in women who are pregnant.

|useInLaborDelivery= There is no FDA guidance on use of Regadenoson during labor and delivery.

|useInNursing= There is no FDA guidance on the use of Regadenoson with respect to nursing mothers.

|useInPed= There is no FDA guidance on the use of Regadenoson with respect to pediatric patients.

|useInGeri= There is no FDA guidance on the use of Regadenoson with respect to geriatric patients.

|useInGender= There is no FDA guidance on the use of Regadenoson with respect to specific gender populations.

|useInRace= There is no FDA guidance on the use of Regadenoson with respect to specific racial populations.

|useInRenalImpair= There is no FDA guidance on the use of Regadenoson in patients with renal impairment.

|useInHepaticImpair= There is no FDA guidance on the use of Regadenoson in patients with hepatic impairment.

|useInReproPotential= There is no FDA guidance on the use of Regadenoson in women of reproductive potentials and males.

|useInImmunocomp= There is no FDA guidance one the use of Regadenoson in patients who are immunocompromised.


|administration=

  • Oral
  • Intravenous

|monitoring=

There is limited information regarding Monitoring of Regadenoson in the drug label.

  • Description


|IVCompat=

There is limited information regarding IV Compatibility of Regadenoson in the drug label.


|overdose=

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Regadenoson in the drug label.


|drugBox=

{{Drugbox2 | Verifiedfields = changed | verifiedrevid = 413312613 | IUPAC_name = 2-{4-[(methylamino)carbonyl]- 1H-pyrazol-1-yl}adenosine | image = Regadenoson2.png | width = 300

| tradename = | Drugs.com = Multum Consumer Information | licence_US = Regadenoson | pregnancy_AU = | pregnancy_US = C | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Intravenous

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ☑Y | CAS_number = 313348-27-5 | CAS_supplemental = 875148-45-1 | ATC_prefix = C01 | ATC_suffix = EB21 | ATC_supplemental = | PubChem = 219024 | DrugBank_Ref =  ☑Y | DrugBank = | UNII_Ref =  ☒N | UNII = 7AXV542LZ4 | KEGG_Ref =  ☑Y | KEGG = D05711 | ChEMBL_Ref =  ☒N | ChEMBL = 1201750

| chemical_formula = | C=15 | H=18 | N=8 | O=5 | molecular_weight = 390.354 g/mol | synonyms = 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- N-methylpyrazole-4-carboxamide }}


|mechAction=


|structure=

This image is provided by the National Library of Medicine.


|PD=

There is limited information regarding Pharmacodynamics of Regadenoson in the drug label.


|PK=

There is limited information regarding Pharmacokinetics of Regadenoson in the drug label.


|nonClinToxic=

There is limited information regarding Nonclinical Toxicology of Regadenoson in the drug label.


|clinicalStudies=

There is limited information regarding Clinical Studies of Regadenoson in the drug label.


|howSupplied=


|fdaPatientInfo=

There is limited information regarding Patient Counseling Information of Regadenoson in the drug label.


|alcohol=

  • Alcohol-Regadenoson interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


|brandNames=


|lookAlike=


|drugShortage= }}


{{#subobject: 

 |Page Name=Regadenoson
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Regadenoson
 |Label Name=Regadenoson11.png

}}


{{#subobject: 

 |Label Page=Regadenoson
 |Label Name=Regadenoson11.png

}}

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)
Retrieved from "https://www.wikidoc.org/index.php?title=Regadenoson&oldid=1002254"